Cargando…

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism

• Management of platinum refractory ovarian cancer is challenging. • Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy. • Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option.

Detalles Bibliográficos
Autores principales:	Lam, Clarissa, Ha, Kristal, Hakam, Ardeshir, Shahzad, Mian M.K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079239/ https://www.ncbi.nlm.nih.gov/pubmed/35540026 http://dx.doi.org/10.1016/j.gore.2022.100992

Ejemplares similares

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival
por: Nakamori, Keita, et al.
Publicado: (2022)

Metastatic uterine tumor resembling ovarian sex cord tumor: A case report and review of the literature
por: Kuznicki, Michelle L., et al.
Publicado: (2017)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Patel, Shetal A., et al.
Publicado: (2021)

Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab
por: Stüven, Anna Kathrin, et al.
Publicado: (2019)

Pembrolizumab in relapsed or refractory Richter syndrome
por: Armand, Philippe, et al.
Publicado: (2020)

Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study
por: Lin, Wenbao, et al.
Publicado: (2022)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
por: Kavanagh, John J, et al.
Publicado: (2010)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma
por: Kao, Chien-Hsiang, et al.
Publicado: (2022)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

[(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
por: Sharma, Rohini, et al.
Publicado: (2019)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
por: Song, Haa-Na, et al.
Publicado: (2018)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
por: Bouhuys, Marleen, et al.
Publicado: (2023)

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
por: Kim, Hye Ryun, et al.
Publicado: (2023)

Levilimab: Thromboembolism and acute renal failure following off label treatment: 2 case reports
Publicado: (2021)

Dexamethasone/prednisone/tofacitinib: COVID-19, thromboembolic episodes and off-label use: case report
Publicado: (2021)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

Efficacy and safety of the combination of paclitaxel and platinum in advanced thymic carcinoma
por: Xu, Jian‐ping, et al.
Publicado: (2015)

Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides
por: Walker, Christina J., et al.
Publicado: (2020)

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients
por: Byers, Lauren Averett, et al.
Publicado: (2017)

An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab
por: Bell, Sarah G., et al.
Publicado: (2021)

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
por: Sandercock, J, et al.
Publicado: (2002)

Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report
por: Kamada, Teppei, et al.
Publicado: (2020)

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report
por: Jiang, Jian, et al.
Publicado: (2020)

A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab
por: Sh Ahmed, Omar, et al.
Publicado: (2022)

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
por: Armand, Philippe, et al.
Publicado: (2019)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis
por: Pei, Rui, et al.
Publicado: (2021)

Off-label use of rituximab in refractory pediatric rheumatic diseases: a single-center experience
por: Aguiar, Francisca, et al.
Publicado: (2014)

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients
por: Chung, Hyun Cheol, et al.
Publicado: (2021)

When is off-label off-road?
por: de Vries, E G E, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1120ni070i8vnn7khaka5hdsc2